Heart Failure: Adaptive Signals Become Chronic Stress

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Neurohormonal explanations support reasoning, but clinical trial evidence and patient priorities determine treatment. Mechanism alone does not establish benefit.

Compensation can become a harmful loop. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Compensation can become a harmful loop. Reduced effective circulation — Heart dysfunction or congestion; RAAS / sympathetic activation — Compensatory signaling; Salt and water retention — Raises filling burden; More cardiac stress — Can worsen the initiating problem. Protective therapy interrupts parts of this loop; indication and tolerance depend on phenotype. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Compensation has a cost

Reduced effective circulation activates sympathetic, renin–angiotensin–aldosterone, and other pathways. These responses can sustain sodium retention and adverse remodeling.

Recognize kidney–heart interaction

Congestion, reduced forward flow, drug effects, and intrinsic kidney disease can all influence renal function during heart failure.

Assess the phenotype

Ejection fraction, valves, rhythm, blood pressure, volume, kidney function, and comorbidities determine which treatment evidence applies.

Name the HFrEF treatment foundations

For eligible HFrEF patients, disease-modifying therapy includes an ARNI or ACEi/ARB, an evidence-based beta blocker, an MRA, and an SGLT2 inhibitor. Loop diuretics treat congestion but are not interchangeable with those outcome-based therapies. Indications and evidence differ in HFpEF.

Use monitoring to preserve benefit safely

After changes, assess BP, symptoms, kidney function, potassium, and volume. New hypotension with poor perfusion differs from an asymptomatic hemodynamic creatinine change. Review interacting drugs and residual congestion before permanently abandoning a beneficial class; severe hyperkalemia or progressive injury requires active reassessment.

Keep the patient outcome central

Neurohormonal explanations support reasoning, but clinical trial evidence and patient priorities determine treatment. Mechanism alone does not establish benefit.

Supporting evidence

Continue learning